FL-JABIL-INC
9.6.2021 14:49:05 CEST | Business Wire | Press release
Jabil Packaging Solutions , a division of Jabil Inc. (NYSE: JBL), today launched its latest packaging prototype: the Eco.bottle® product platform for VITTEL® , a leading mineral water brand in Europe from the water division of Nestlé. Designed for scalability by a team including Ecologic Brands , acquired by Jabil earlier this year, the VITTEL® hybrid bottle leverages paper and plastic components, resulting in a plastic reduction of more than 50 percent compared to VITTEL®’s current 1-liter bottle. Moreover, this bottle features a patent-pending, first-of-its-kind tear strip, enabling easy separation of the paper and plastic components for an efficient, consumer-friendly recycling experience. This breakthrough innovation is comprised of 100 percent recycled paper and plastic materials, creating a circular system from readily available, high-volume waste streams. Consumer testing in Europe will begin in June and the bottle will be showcased to the media during the upcoming Tour de France, taking place June 26, 2021 through July 18, 2021.
“True innovation in sustainable packaging requires a holistic view of the product that goes beyond aesthetics, material selection and design features,” said Julie Corbett, senior business unit director of Jabil and founder of Ecologic Brands. “Our goal is to innovate around the entire life cycle of the bottle, not only to decrease the use of plastic. That’s why the Eco.bottle® product platform is engineered to drive plastic reduction, improve carbon footprint and optimize the consumer recycling experience.”
Constructed of 80 percent paper and only 20 percent recycled plastic (cap included), the VITTEL® hybrid bottle’s two-shell system, enabled by interlocking paper tabs, allows for nesting during transit and warehousing. This eliminates extra space in the supply chain and has the potential to lessen the amount of trucks needed for delivery by 50-60 percent.
The VITTEL® hybrid bottle project began in 2020; in less than one year, VITTEL® and Jabil have successfully delivered one of the world’s first hybrid water bottles. VITTEL’s deep knowledge of mineral water bottling helped achieve the thinnest 1-liter plastic liner in the market today, which uses just 9.2g of recycled plastic. Jabil’s conversion technology and expertise enabled the fabrication of an elegant and functional outer shell made of certified Forest Stewardship Council reclaimed and recycled material.
“It’s no longer enough for CPG companies to say they’ve reduced their waste. They now also need compelling solutions for repurposing that waste,” said Jason Paladino, senior vice president of Jabil and CEO of Jabil Packaging Solutions. “Jabil’s Box-to-Bottle® manufacturing platform allows us to take our customers' waste and incorporate it into our manufacturing process within our facilities in Manteca, California and Tortosa, Spain. This fully accountable and traceable manufacturing platform provides forward-thinking brands like VITTEL® with unparalleled visibility into the circularity of their products.”
“Thanks to Jabil’s innovative Eco.bottle® product platform, the VITTEL® hybrid bottle is the result of a journey launched several years ago to explore options for drastically reducing the proportion of plastic in our packaging,” said Laure Goutagneux, VITTEL® marketing director. “We are thrilled with the results of our collaboration, including a plastic reduction of 50 percent when compared to our current lightweight bottles.”
About Jabil :
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005197/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom